Patients with the most severe manifestations of lower extremity arterial occlusive disease often require peripheral bypass surgery for limb salvage and preservation of function. Although good quality saphenous vein offers the most durable conduit for reconstruction, 5-year failure rates are 30-50% and have remained largely unchanged for the past two decades. The majority of these failures occur within the first year of implantation, which is regarded as the most biologically active time during which the vein graft adapts to the arterial environment. Although intimal hyperplasia is generally regarded as the primary culprit of vein graft failure, geometric remodeling of the healing vein graft has recently emerged as a potentially significant contributing factor. While hemodynamic forces, including an increase in shear stress and wall tension, are undoubtedly central to the magnitude and direction of vein graft remodeling, we have determined that these forces alone cannot account for the extent of variability noted in early remodeling patterns. Therefore, we hypothesize that circulating factors, such as mediators of inflammation, may modulate the vein graft response to mechanical forces. This article reviews the definition and diagnosis of vein graft failure and summarizes our current efforts to understand the mechanisms of normal and abnormal vein graft adaptation to the arterial environment.
Introduction
We are now into the seventh decade of modern vascular reconstructive surgery for lower extremity ischemic disease. Early advances in peripheral vascular reconstruction were largely technical in nature. However, perhaps none was more profound than the recognition and mastery of use of the greater saphenous vein as the conduit of choice for performing complex procedures such as the femoropopliteal bypass. 1 First applied by Kunlin in Germany in 1949 2 and later championed by early American pioneers in vascular surgery Robert Linton, Clement Darling, and John Mannick, its use allowed for infra-popliteal reconstructions with patency and limb salvage rates more comparable to proximal reconstructions. Maturing in parallel with these advances were improvements in imaging procedures, with the development of contrast angiography, anticoagulation with the discovery of hep-arin sulfate, and pre-operative and peri-operative care, all of which have led to a significant reduction in the morbidity and mortality of lower extremity bypass surgery.
The efficacy and durability of the vein graft conduit in lower extremity bypass surgery has been defined. [3] [4] [5] However, advances in the understanding and, ultimately, modulation of the biology of vein graft failure have not kept pace with the technical achievements of the later half of the last century and, to date, vascular surgery can claim little over the province of intimal hyperplasia. This is manifest by relatively little change in the 30-50% 5-year vein graft failure rates over the past several decades. These failures are accompanied by significant amounts of disability and limb loss resulting in increased resource utilization for the health care system and in a diminished quality of life for the patient. 6, 7 In the lower extremity vein graft, there are three distinct temporal phases of failure. 8 Early graft occlusion (i.e. within 30 days), which occurs in 5-10% of cases, is generally ascribed to technical complications of the surgery but also includes problems intrinsic to the conduit (e.g. small diameter vein, pre-existing vein pathology, retained valve) as well as extrinsic etiologies (e.g. limited outflow, hypercoagulability). Mid-term (3-24 months) and late (> 2 years) vein graft failures are most commonly ascribed to the development of intimal hyperplasia and progression of atherosclerotic degeneration in the native arterial tree, respectively. 5, 9 Most efforts to alter the natural history of graft failure have focused on modulating the intimal hyperplastic response, which is presumed to be responsible for the majority of failures. However, our inability to significantly impact vein graft failure is largely the result of our failure to understand basic pathophysiological mechanisms involved in normal vein graft healing: there is undoubtedly a complex interplay between the hemodynamics of the arterial circulation in which the vein is placed, the circulating factors in which the vein is bathed, and the intrinsic biology of the vein itself.
Regardless, there can be no escaping that the lower extremity vein bypass procedure is an extremely technically demanding operation and favorable hemodynamics or biology will never overcome a poor technical performance. Preimplantation vein disease, the use of high-risk conduits (e.g. arm vein, spliced veins, vein lumen < 3 mm), redo bypass procedures, or compromised outflow targets have been shown to unfavorably impact patency. 10, 11 The reader is referred to one of a number of excellent treatments of these technical factors. [12] [13] [14] Herein, we outline our current efforts to better appreciate vein graft failure from a pathophysiological perspective, starting with the assumption of an adequate vein and a technically adequate surgery.
The diagnosis of vein graft failure: rationale for surveillance Regardless of mechanism, thrombosis is the final common pathway of a failed graft, which can be defined as a graft that has lost its patency. This is in contradistinction to the failing grafta graft that has one or multiple hemodynamically significant stenosesthat, if unrepaired, may lead to a failed graft. Unlike aorto-coronary grafts, the superficial location of the lower extremity vascular bypass allows for surveillance of the graft for hemodynamically significant stenoses that could threaten its patency and function. The premise of duplex surveillance is predicated on the fact that vein grafts fail by progressive high-grade stenoses that can be reliably and accurately detected by non-invasive imaging and the generally poor salvage rate of occluded grafts. 15 Seventy to eighty percent of high-grade stenoses will progress to vein graft failure. 16 Surveillance provides prompt detection of stenoses, allows monitoring for progression, and allows for timely and appropriate therapeutic intervention (e.g. percuta-neous angioplasty, vein patch angioplasty, or interposition graft). 17 Most reports suggest that patency of the graft can be improved by 10-15% by a careful postoperative surveillance program. 15, 18 Vein grafts that demonstrate stenoses and are successfully revised should continue to undergo vigilant surveillance, as approximately one-third will have subsequent hemodynamically significant stenoses. 19 Etiologies of the stenoses vary depending on the site and distribution of the lesion. 8, 17 A discrete, focal, stenoses located mid-graft may be caused by a valve site stenoses, graft torsion, a retained valve leaflet, or a focal area of vein injury during harvesting. More diffuse intimal hyperplasia involving long segments of the vein or multiple tandem lesions are more likely to be caused by ineffective remodeling of the conduit and exuberant intimal hyperplasia.
Overall, approximately 50% of lesions responsible for vein graft failure are juxta-anastomotic, 30% are located within the body of the graft, and the remainder are within the native arterial inflow or outflow sites. 8 Although there are no specific guidelines regarding vein graft surveillance, most authorities define a hemodynamically significant stenoses as a peak systolic velocity greater than 300 cm/s, peak systolic velocity ratio (PSVR) of a stenotic region divided by a normal reference region of graft > 3.5, or a drop in ankle-brachial index by 0.15 ( Figure 1 ).
Reporting standards have recommended defining bypass graft endpoints into three categories: primary patency, primary-assisted patency, and secondary patency. 20 Primary patency is defined as uninterrupted patency with no procedure or intervention directly performed on the bypass graft. By definition, a program with a more aggressive duplex surveillance program and with a low threshold for intervention on ultrasonographic-detectable stenoses will have a lower primary patency rate than a program without these, suggesting that this endpoint is somewhat arbitrary. Primary-assisted patency is defined as the situation whereby patency is never lost but is maintained by prophylactic intervention such as balloon angioplasty or revision of a stenoses detected in the bypass graft. This is less arbitrary in that it allows for revisions, percutaneous or open, and the difference in survival curves between primary and primary-assisted is the inclusion of all grafts that developed stenoses on the screening program and underwent intervention. This is a 'harder' clinical endpoint and is preferred by some clinical scientists. The secondary patency rate is defined as the time from implantation until the graft is occluded and abandoned. The difference between secondary and primary-assisted patency is that secondary patency includes all bypass grafts that were revised (thombolysis or mechanical thrombectomy) after becoming occluded ( Figure 2 ). From a clinical endpoint perspective, both primary and secondary patency rates are important. Primary patency is a measure of the natural history of the graft or reconstructive procedure whereas secondary patency is a measure of how long function of the graft can be preserved. 20 Population characteristics: a moving target in the 21st century
The combination of an aging population and an epidemic of abnormalities in glucose homeostasis (insulin resistance, metabolic syndrome, and diabetes mellitus) has shifted the characteristics of patients presenting for lower extremity bypass into ones with increasingly complex comorbidities and challenging anatomy. 21 In contrast to patients presenting for cardiac reconstructions, lower extremity bypass patients are generally older, and with higher proportions of women, diabetics, and those with renal insufficiency (Table 1) . 22, 23 As transcatheter therapeutics become more universally applied, the numbers of first-time proximal reconstructions (femoral to above-knee popliteal) are giving way to more distal bypasses, often times re-do bypasses, and those requiring the use of alternative vein sources other than the ipsilateral greater saphenous vein. Figure 1 Representative example of a stenoses detected in a lower extremity bypass graft by surveillance duplex ultrasound. The patient is a 68-year-old African American woman with coronary artery disease, diabetes mellitus, and end-stage renal disease who underwent common femoral artery to posterior tibial artery bypass with a single-segment, non-reversed greater saphenous vein for a non-healing heel ulcer. Forty days after the procedure, she underwent duplex ultrasound examination, which revealed normal flow profiles and velocity in the proximal graft segment (A). However, the peak systolic velocity increased from 73.7 to 481.1 cm/s in the distal segment of the graft (C). Because the peak systolic velocity was greater than 300 cm/s and the velocity ratio was greater than 6, an angiogram was obtained. The angiogram confirmed normal proximal graft (B) and severe stenoses in the distal aspect (D: single arrow). The distal anastomosis is denoted by the double arrows. She underwent vein patch angioplasty 50 days after her index operation, her ulcer has since healed and is she ambulatory. Patients undergoing lower extremity bypass are demographically distinct from patients undergoing coronary bypass: diabetes mellitus, renal failure, hypertension, and cerebrovascular disease are more prevalent. Results taken from PREVENT III (lower extremity cohort) 22 and PREVENT IV (coronary bypass cohort) 23 trials.
At our own institution, we have witnessed a profound increase in diabetes and renal disease in patients presenting for lower extremity bypass in the two decades between 1978 and 1998. 21 The mean glomerular filtration rate (eGFR) in a recent series of 456 patients undergoing lower extremity bypass was 67 ml ⋅ min -1 ⋅ 1.73 m -2 [chronic kidney disease (CKD) category 2], and a remarkable 50% had renal insufficiency defined as eGFR < 60 ml ⋅ min -1 ⋅ 1.73 m -2 (CKD 3 or lower), and 30% were dialysis dependent (CKD 5). 24 Patients with diabetes and renal impairment often present with tissue necrosis (gangrene or ulceration) and have a propensity for advanced disease in the tibial distribution, which limits the applicability and effectiveness of endovascular therapy and mandates open surgical reconstructions to the distal tibial or pedal levels.
The biochemical signature of the patient presenting for open lower extremity revascularization in the 21st century is marked by an inflammatory phenotype. 25 In a prospective study of 91 patients undergoing lower extremity bypass, we examined the association of pre-operative levels of highsensitivity C-reactive protein (hsCRP), serum amyloid A, (SAA), and fibrinogen on future cardiovascular and graft-related events. We found that the median hsCRP level was 3.25 mg/l, which places this population squarely within the highest risk tertile for future cardiovascular events as defined by the American Heart Association. 26 Levels of all three inflammatory markers were significantly higher in patients presenting with critical limb ischemia as compared to those presenting with claudication and correlated with diabetes and renal failure. However, only hsCRP levels predicted future cardiovascular and graft-related events. Dichotomizing patients by plasma hsCRP levels above or below 5 mg/l (upper limit of normal of our laboratory) predicted a composite of adverse cardiovascular events (MI, stroke, death, or graft failure), most of which were graft related (fully adjusted hazard ratio of 2.28; 95% confidence interval 1.15 to 4.51, p = 0.018). Whether or not CRP is a marker of overall systemic inflammation or whether it is an actual bio-modulator within the vessel wall, as reported by some, remains to be elucidated.
Although diabetes has never been shown to be an independent predictor of lower extremity vein graft failure, 22, 24 it is associated with an inflammatory phenotype and has been shown to increase the risk of peripheral artery disease two-to fourfold. 27 This is likely to significantly impact vascular medicine and surgery practices. In the United States, it is estimated that the lifetime risk for developing diabetes for the cohort born in the year 2000 is 32.8% for males, 38.5% for females and as high as 52.5% for Hispanic females. 28 Indeed, as defined by the World Health Organization, 29 currently 64% of the patients presenting for peripheral bypass have diabetes and approximately 50% have metabolic syndrome. 22 These patients have high levels of circulating markers of inflammation, dyslipidemia (low HDL and high triglycerides), and impaired endothelial function. 30 Therefore, it is likely that the intersection of metabolic syndrome, inflammation, and renal impairment place the graft at highest risk. 31 However, the interplay of these systems and the exact mechanisms by which they effect intimal hyperplasia or vein graft remodeling is currently unclear and is part of ongoing investigations.
Normal vein graft maturation: on growth and form 32
Experimental physiologists and students of developmental vascular biology have long recognized that the anatomic caliber of a blood vessel varies with the volume that flows through it in such a way that blood is delivered to its vascular bed as efficiently as possible in accordance with the principle of 'minimum work' of the system. 33, 34 It was later recognized that an intact and functioning endothelium was absolutely necessary for the vessel to properly respond acutely to changes in blood flow, 35 and that nitric oxide (NO) was the soluble biologic mediator responsible for such transformations. 36 Pathological observations of the human left main coronary artery revealed that adult arteries were not static conduits but rather underwent compensatory enlargement in order to preserve the lumen in the setting of an encroaching atherosclerotic plaque. This is thought to be an adaptive response to a chronic increase in shear stress at the site of the lesion. 37, 38 These observations have been fortified by the use of high-resolution intravascular imaging modalities that have captured the in vivo dynamic nature of adult human arteries in response to injury or vasoactive mediators. [39] [40] [41] Taken together, these seminal observations provide the foundation for our current working model of blood vessel homeostasis and caliber regulation and with it our modern understanding of vascular remodeling. 42 Remodeling can be defined as a dynamic process of structural alteration in the conduit that involves changes in cellular processes and extracellular matrix and fibrous protein (collagen and elastin) metabolism. This process is dependent on a dynamic interaction between locally and remotely generated growth factors, vasoactive substances, and hemodynamic stimuli. 43 However, our current understanding of remodeling as a response to injury in humans has largely been defined within the context of balloon injury to arteries. Furthermore, important structural, physiological, and biochemi-cal differences between artery and vein merit careful consideration on the extent to which we can generalize these findings. The normal greater saphenous vein has a thin intima covered by a continuous layer of endothelium. The internal elastic lamina rudimentary and the media, consisting of a thin inner layer of longitudinal muscle fibers and a more prominent outer layer of circular muscle fibers, is much thinner than an artery. 44 A thinner media may impair its capacity to contract or relax in response to hemodynamic stimuli to the same extent as an artery can. Differences in endothelialdependent relaxation have been shown between veins and arteries both ex vivo [45] [46] [47] and in vivo. 48 This suggests fundamental variability in eNOS gene or protein expression levels or NO bioavailability in different endothelial beds. Recently, similar differences have been observed in smooth muscle cell phenotypes from coronary arteries and saphenous veins reflecting distinct responses to stimuli. 49, 50 There are also differences in prostacyclin production and cell surface adhesion molecule expression that may impact both vasomotor function and interaction with circulating blood elements. [51] [52] [53] The idea that vein graft adaptation to arterial flows and pressures may be important to its functional capacity and survival dates back at least 30 years to investigations exploring fundamental differences in the mechanical properties of arteries and veins. 54 Veins placed in the arterial circulation as bypass conduits are universally subjected to acute increases in pressure and pulsatile hemodynamics, resulting in acute increases in wall shear and radial stress (Figure 3 ). Trauma during harvesting, prebypass morphological changes, and ischemiareperfusion during the procedure may impact the ability of the vein to adapt to these forces. 44, 55, 56 Recent efforts at our institution have focused on in vivo methods to elucidate normal patterns of remodeling in human subjects and to clearly define the magnitude, variability and time course of this process. Using high-resolution duplex ultrasound to examine the same vein segment at pre-specified time points (intra-operatively, 1, 3, 6, and 12 months), we sought to identify key remodeling metrics to characterize vein healing and early correlates of maladaptive patterns of remodeling ( Table 2 ). This work demonstrated that normal vein graft maturation is associated with two distinct phases of remodeling: an early pattern dominated by luminal enlargement followed by a later phase of vein graft thickening and stiffening. 57, 58 Early lumen dilation is most pronounced in the first month after surgery. 57 In a study of 96 lower Figure 3 Vein bypass conduits are subject to acute increases in shear stress (top) and wall tension (bottom) overlayed with pulsatile flow. The initial shear stress is a function of flow, Q, and radius, r, and is the most significant predictor of vein graft dilation in the first month after implantation into the arterial circuit. Possible molecular mediators of shear stress stimuli include nitric oxide (NO), endothelial-derived hyperpolarizing factor (EDHF) and prostacyclin. Wall tension is a function of pressure, P, radius, r, and wall thickness, w. Vein grafts thicken over 1-3 months to normalize increased wall tension. Known components of increased wall thickness include vascular-smooth muscle cell proliferation and migration, graft-extrinsic cell recruitment, fibrous protein synthesis, and matrix metalloproteinases (MMPs) and tissue inhibitors of metalloproteinases (TIMPs), which reorganize extracellular matrix components and restructure the vein graft wall. extremity bypass grafts, the mean diameter increase from surgery to 1 month was 21.6% and initial shear stress was the single biggest predictor of percent lumen change: R = 0.54, p = 0.03 (Figure 4) . 57 The observation of shear-dependent early remodeling immediately evokes the endothelium as a permissive, if not, crucial factor in the ability of the vein to react to the increase in flow. Endothelial dysfunction may link the apparent association between systemic inflammation and remodeling.
More recently, we observed that systemic inflammation, as determined by circulating plasma hsCRP levels, modulates the early remodeling capacity of vein grafts. 59 In a prospective cohort of 75 patients undergoing lower extremity vein bypass procedures in which both CRP and remodeling data were available, individuals with elevated hsCRP (defined as ≥ 5 mg/l) had significantly less early lumen dilation then those with lower hsCRP levels: 13.5% vs 40.9%, p = 0.0072. There was a strong negative linear relationship between CRP and percent change in lumen dilation between surgery and 1 month: R = 0.40, p = 0.01. 59 In addition, vein grafts placed in patients with normal or low hsCRP dilated appropriately to shear stress, whereas those with elevated hsCRP did not.
The vein graft compensates for an acute increase in wall tension by increasing wall thickness. From a material science perspective, this is reflected by an increase in the elastic modulus and an increase in overall stiffness. These values can be estimated by calculating the pulse wave velocity (PWV) and using the Moens-Korteweg equation. 57 In contrast to the early (0-1 month) lumen diameter change, the majority of stiffening of the vein graft takes places over the 1-3-month time frame ( Table 2 ). The increase in the elastic modulus cannot be explained by changes in wall thickness alone and therefore suggests changes in wall composition. In comparison with other wall components (elastin, proteoglycans, cells), collagen has an elastic modulus that is about one thousand times greater and suggests that Figure 4 Human lower extremity vein grafts display distinct phases of geometric remodeling. Serial in vivo measurements of lower extremity vein grafts using highresolution duplex ultrasound revealed that the most pronounced lumen dilation occurs in the first month after surgery (A). The mean diameter increase during this period was 21.6% and initial shear stress was the single biggest predictor of percent change, R = 0.54, p = 0.03 (B). By contrast, vein wall stiffness increased most significantly during months 1-3 (C as the vein adapts, collagen content increases out of proportion with other wall constituents. These fundamental changes in vein wall composition are exemplified by the fact that at 6 months after implantation, the vein is 94% stiffer than the native superficial femoral artery: 3.3 versus 1.7 megadynes/ cm ( Figure 4 and Table 2 ). 58 These in vivo human data are consistent with observations made in canines 30 years ago by a fourth year medical student 54 and represent preliminary efforts to detail vein graft changes in humans. There has been relatively little focus on this area over that time frame, 60, 61 and several important questions remain: (i) does early outward remodeling predict future graft patency?; (ii) what is the most favorable lumen area to wall area ratio in functioning grafts?; (iii) is outward remodeling related to overall endothelial health of the patient?; (iv) does the level of inflammation of the patient (as measured by hsCRP) modulate the ability of the vein to remodel appropriately?; (v) does the level of systemic inflammation affect material properties within the wall (increase in adventitial fibrosis)?; and finally, (vi), can specifically targeting vascular inflammation affect vein graft remodeling and thus favorably impact patency?
Ultimately, the final question is, can a vein become an artery? While somewhat theoretical, it is of interest that every vascular surgeon who has been practicing limb salvage therapy for a period of time has accumulated in his or her practice a number of patients who have enjoyed a patent and functioning vein graft for 10 years or more. Perhaps, rather than study our failures, we should study our successes.
Epidemiology of vein graft failure: from observational studies to a randomized controlled trial
The natural history of the lower extremity bypass with autogenous vein has been described mostly by large, retrospective, single-center series. These are from tertiary hospitals where the surgeons have an interest in complex limb salvage therapy and the results may not be reflective of real-world community care. Surprisingly, what has emerged from these trials is that traditional Framingham-based cardiovascular risk factors (e.g. age, male sex, diabetes mellitus, total cholesterol, hypertension), with the possible exception of smoking, have largely failed to predict which patients are at risk for vein graft failure, suggesting that the hazard for failure is mediated by other variables. The implication is that the pathogenesis of the mid-term vein graft failure is fundamentally different from atherosclerosis and likely relates to the kinetics of intimal hyperpla-sia occurring rapidly over a relatively short time frame (0-12 months), as opposed to that of atherosclerosis, which develops gradually over years to decades. It is quite possible that these traditional risk factors may be involved in late vein graft loss (5-10 years) where there is an approximate 5% attrition rate per year. However, this supposition has not been rigorously studied.
The lack of significant association between vein graft failure and traditional risk factors has prompted numerous authors to explore the role of so-called novel risk factors such as homocysteine, fibrinogen, hsCRP, and lipoprotein (a) in the pathogenesis of vein graft failure. 25, [62] [63] [64] It is difficult to come to meaningful conclusions based on these studies as many of them have short follow-up (< 1 year) 65, 66 ; measured the markers after the occlusive event 67 ; included revascularization procedures such as carotid endarterectomy or percutaneous procedures; included non-autogenous conduits such as PTFE 62, 65, 66 ; conducted analysis without multivariable adjustment 64 ; or failed to account for important known co-variates. 63 Clearly, an area of active ongoing investigation is the development of biomarkers and risk profiles of vein graft failure.
There are also important racial disparities in both the presentation of and outcomes after lower extremity bypass surgery. African American patients tend to be younger, predominantly female, and have greater prevalence of diabetes, hypertension, and dialysis-dependent renal failure at the time of bypass. 24, 68 Despite these differences, multivariable analysis revealed that the adjusted hazard ratio for loss of primary graft patency in African Americans versus Caucasians was 1.47. It is unclear whether this finding is the result of an unmeasured co-variate that is influencing outcome or represents a true biologic difference in intimal hyperplasia formation, remodeling, or disease progression. Clearly, there needs to be more investigation into this important observation.
The era of large, multi-center, double-blinded, placebo-controlled randomized trials of therapy for vein graft disease arrived with the publication of a series of PREVENT (Project of Ex-vivo Vein graft Engineering via Transfection) studies, 22, 23, 69 which tested the hypothesis that ex vivo delivery of oligodeoxynucleotide decoy to the E2F transcription factor could improve primary patency or limb loss. This was an inclusive trial that enrolled 1404 patients with critical limb ischemia (rest pain, ulceration, or gangrene) in 83 centers across the United States and Canada. Both academic and nonacademic vascular surgeons participated in the trial and both the patients and the results are felt to be representative of the general population. The 1-year primary, primary-assisted, and secondary patency rates in the PREVENT III trial were 61%, 77%, and 80% respectively, and the limb salvage rate was 88%. While the trial failed to demonstrate efficacy, these studies demonstrated the feasibility of a locally delivered molecular therapy for vein graft failure and also underscored our limited understanding of the underlying pathophysiology of the problem.
Biologic mechanisms of vein graft failure: a paradigm shift with potential therapeutic implications A full description on the molecular pathways involved in vein graft failure is well beyond the scope of this manuscript and the reader is referred to one of several excellent treatments of the topic. 5, 9, 55, 70 Nevertheless, a number of recent observations have impacted our current understanding of intimal hyperplasia formation with potential therapeutic implications. Historically, it has been thought that the cells constituting the classic intimal hyperplastic lesion responsible for the majority of vein graft stenoses are derived from intrinsic vascular medial smooth muscle cells (SMCs) that undergo a change from a contractile to a secretory phenotype (de-differentiation) . Briefly, the model asserts that soon after implantation, medial SMCs demonstrate a change in the balance between proliferation and apoptosis and migrate through the rudimentary internal elastic lamina into the (neo)-intima, where further proliferation is accompanied by sustained extra-cellular matrix and fibrous protein production and deposition. 9, 71, 72 These lesions are dense, white, and fibrous in gross appearance. Histologically, they are characterized by an amorphous sheet of cells and matrix ( Figure 5 ). However, recent animal studies have clearly shown that the intimal hyperplastic lesion is a complex of cells from diverse origins, including peri-adventitial fibroblasts, bonemarrow-derived progenitor cells, SMC progenitor cells from neighboring muscle or distinct subsets of vascular SMCs within the media ( Figure 6 ). [73] [74] [75] [76] [77] While there is undoubtedly some species variability, it is interesting to note that in mouse models, as many as 60% of the neo-intima is comprised of cells originating from outside the adventitia of the graft. 76 A more complete understanding of this goes beyond intellectual curiosity as it may potentially have an implication to some directed therapeutics. Anti-proliferative therapy directed at smooth muscle cells within the graft may not affect the recruitment and proliferation of these so-called graftextrinsic cells. This may, in part, explain the failure of anti-proliferative approaches at significantly reducing intimal hyperplasia in human trials. Is it possible to selectively admit desirable cells (endothelial progenitor cells) while screening out undesirable cells immigrating into the healing vein? To do this will require a more complete understanding of the molecular biology of these extrinsic cells in order to develop better therapeutics to leverage their recruitment in favor of better healing. A call for therapeutics: an unmet clinical need and a clinician's wish list
There are approximately two million angioplasties, and 100,000 lower extremity and 450,000 cardiac revascularizations performed annually in the United States. To date, the quest for pharmacologic agents to prevent vein graft stenoses has been a frustrating saga in vascular biology. Encouraging data from cell culture, animal models, and even early phase clinical trials have not borne meaningful clinical fruit. 22 Why should this be? Possibilities include the wrong choice of target; correct choice of target but insufficient understanding of the pharmacokinetic-pharmacodynamic profile of the molecule resulting in inappropriate dosing, inappropriate scheduling, or the wrong delivery mechanisms; lack of surrogate endpoints or biomarkers to test the ability that the biochemical hypothesis was achieved; and finally, misunderstanding the strengths and weaknesses of animal models. 78 The silo hypothesis of one ligand-receptor interaction producing one phenotype is dead. New strategies, which recognize the redundancies in place within the system and perhaps leverage these to therapeutic advantage, must be adopted.
Emerging data suggest that inflammation plays a critical role in the initiation, progression, and complications of graft stenoses. One hypothesis is that by inhibiting endothelial functionincluding barrier regulation, thrombogenicity, production of vasoactive compounds, and leukocyte adherenceinflammation modulates the ability of the vein to appropriately remodel in the arterial circulation, which leads to lumenal encroachment by intimal hyperplasia and vein graft failure (Figure 7 ). Yet, there is no single class of agents that specifically target vessel wall inflammation. While numerous agents have been shown to lower plasma hsCRP levels in various disease states, no class has been shown to be as effective as the HMG-CoA reductase inhibitors. 81 For example, atorvastatin has been extensively demonstrated to lower hsCRP levels in a dose-dependent fashion. [80] [81] [82] It is intriguing that in a small retrospective study, patients taking statins at the time of lower extremity bypass demonstrated an increase in graft survival over those who were not. 83 Vein graft failure is a balance between vessel remodeling and intimal hyperplasia. While genetic engineering of vein grafts to control the exuberant intimal hyperplasia response holds some promise, 84 wholesale improvements in graft patency have not impacted clinical practice. To solve this problem, engineers, imaging specialists, medicinal chemists, and basic and clinical investigators need to work together in mechanistic studies to foster drug discovery and the identification of new molecular targets, develop imaging modalities, create blood and tissue repositories, and validate surrogate endpoints and biomarkers. For example, local delivery platforms not only necessitate an understanding of molecular biology and binding kinetics but also an appreciation of material science and transport phenomena in biologic systems to deliver the compound to the desired target.
Finally, we leave the reader with a wish list that will require continued translational efforts: (i) a better understanding of the mechanisms involved in normal and abnormal vein graft adaptation; (ii) a better appreciation of the balance between remodeling and intimal hyperplasia; (iii) a more complete understanding of interactions between the fluidphase elements, the endothelium, and remodeling; (iv) development of therapeutics that move away from indiscriminant cell-cycle inhibition (paclitaxel, sirolimus) towards selective anti-proliferative therapy that does not result in delinquent reendothelialization after implantation; (v) specific therapeutics that target systemic and vascular wall inflammation; and (vi) the development of drugs or biologics tha accelerate re-endothelialization. 
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